Lege Artis Medicinae

[PATHOPHYSIOLOGY, DIAGNOSIS AND THERAPY OF THE EXTRAOESOPHAGEAL MANIFESTATIONS OF GASTRO-OESOPHAGEAL REFLUX DISEASE]

ROSZTÓCZY András

MARCH 19, 2007

Lege Artis Medicinae - 2007;17(03)

[Recently, considerable interest has been focused on the extra-oesophageal manifestations of gastro- oesophageal reflux disease. Vago-vagal reflex mechanisms have been shown to play a leading role in the pathogenesis of the extra-oesophageal manifestations. In addition, proximal reflux and subsequent chemical irritation of the respiratory tract mucosa are important factors in the development of respiratory symptoms. In contrast to the uncomplicated cases of gastrooesophageal reflux disease, the recognition of these variations may pose a diagnostic challenge right because of the lack of typical symptoms. Successful diagnosis rests with the cooperation of the general practitioner, the specialist observing the extra-oesophageal symptom and the gastroenterologist. The establishment of the pathogenic role of gastro-oesophageal reflux may require verification by oesophageal functional tests. Treatment is based on long-term administration (for at least 3 months if respiratory symptoms are present) of an increased-dose proton pump inhibitor. In the long term, laparoscopic anti-reflux surgery is a realistic alternative to medical treatment in suitable patients. Dietary and life-style education of patients has an important complementary role in the successful long term management.]

COMMENTS

0 comments

Further articles in this publication

Lege Artis Medicinae

[A Poem Cycle by Zsuzsa Tamás – Pictures by Tímea Fodor]

Lege Artis Medicinae

[Cooperation of the cytopathologist and the radiologist in cytodiagnostics]

JÁRAY Balázs, SZÉKELY Eszter, ISTÓK Roland, WINTERNITZ Tamás, TARJÁN Zsolt, TÓTH Anna, GYŐRI Gabriella, PÉNTEK Zoltán, EGYED Zsófia, NÁDOR Katalin

Lege Artis Medicinae

[Health Learning and Rehabilitation]

KELEMEN Gábor

Lege Artis Medicinae

[BISPHOSPHONATES IN THE TREATMENT OF BONE METASTASES]

NAGYKÁLNAI Tamás

[Bisphosphonates are used in the treatment of malignant diseases with bone metastases and of osteoporosis. The currently available bisphosphonates have a wide range of effectiveness, tolerability and dosing profiles. In metastatic disease, bisphosphonate therapy is aimed at the correction of hypercalcaemia and the reduction of skeletal-related events due to malignancy metastatic to bone. Large clinical trials have shown that long-term administration of bisphosphonates can reduce skeletal-related events by 30 to 40% and significant analgesic effect is reached in at least 50% of the patients. The superiority of zoledronate to the old standard pamidronate has been proved in large randomized trials. Despite the fact that bisphosphonates are generally well tolerated, certain toxicities such as renal toxicity and osteonecrosis of the jaw should be considered with prolonged use.]

Lege Artis Medicinae

[The Command of Self-Awareness Work A Discussion with dr. Emőke Bagdy]

FERENCZI Andrea

All articles in the issue

Related contents

Lege Artis Medicinae

[THE USE OF ACID SUPPRESSANTS IN PANCREATIC DISEASES]

GERVAIN Judit

[The histamine-2 receptor antagonists and the proton pump inhibitors are part of current therapeutic protocols for most diseases of the pancreas. Acid suppression is definitely recommended to improve the effect of enzyme supplements in chronic pancreatitis and in maldigestion that develop after certain gastric and pancreatic surgeries. For this purpose proton pump inhibitors should be used since they are effective and provide lasting inhibition. In cystic fibrosis, their use is indicated already in the sub-clinical stage and they are also part of the basic protocol for the treatment of Zollinger-Ellison syndrome. Acid suppressants are not routinely used in the therapeutic protocols of acute pancreatitis. Their use is well-grounded in necrotizing pancreatitis in the stage of multiple organ failure to prevent the development of stress ulcer. During enteral tube feeding, their use is indicated to protect the permanently empty stomach and because of the frequent reflux symptoms. The risk of bacterial overgrowth, which is often considered a contraindication, is insignificant if jejunal tube feeding is applied and antibiotic treatment is frequently administered.]

Lege Artis Medicinae

[CLINICAL ASPECTS OF NOCTURNAL GASTRO-OESOPHAGEAL REFLUX]

DEMETER Pál

[Gastro-oesophageal reflux that occur at night has special clinical features and thus require extra attention. During sleep most anti-reflux mechanisms diminish, which results in prolonged contact between gastric acid and oesophageal mucosa compared to reflux during the day. Nighttime reflux symptoms adversely affect quality of life, vitality, physical and mental health. A further important consequence is the potential exacerbation of respiratory disorders such as asthma and sleep apnea. There is increasing interest in the association between nocturnal reflux and certain extra-oesophageal symptoms, including reflux laryngitis and chronic cough. An increased risk of erosive damage and adenocarcinoma of the oesophagus are also observed among patients who report nocturnal reflux symptoms. The primary goal of treatment is to improve quality of life and reduce the risk of complications by decreasing the time of acid contact with oesophageal mucosa. Nighttime reflux symptoms are much more difficult to control than daytime symptoms. Treatment guidelines generally recommend lifestyle changes as the initial approach in managing nocturnal symptoms, however, this is successful in only a small proportion of patients. Evidence-based reviews and meta-analyses favour the use of proton pump inhibitors in the treatment of gastro-oesophageal reflux disease and reflux-oesophagitis. Proton pump inhibitors are the most efficient acid-suppressing agents and thus diminish the harmful effect of acidic gastric reflux on the oesophageal mucosa. In addition, by decreasing the volume of gastric acid, they reduce the tendency to reflux.]

Hypertension and nephrology

[About the care of patients with hyperuricaemia and gout]

[This consensus document is intended to provide guidance for the effective and efficient treatment of asymptomatic individuals with high uric acid levels and gout patients.]